Home>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Erlotinib mesylate

Erlotinib mesylate Sale

(Synonyms: 埃罗替尼甲磺酸盐; CP-358774 mesylate; NSC 718781 mesylate; OSI-774 mesylate) 目录号 : GC36003

An EGFR tyrosine kinase inhibitor

Erlotinib mesylate Chemical Structure

Cas No.:248594-19-6

规格 价格 库存 购买数量
100mg
¥450.00
现货
500mg
¥1,080.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

Description

Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity (IC50 = 2.5 ?M).1,2 This inhibits tumor growth in human head and neck carcinoma HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg.1 Erlotinib also suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 ?M) and JAK2 mutant JAK2V617F positive hematopoietic progenitor cells (IC50 = 5 ?M), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia.3,4 Formulations containing erlotinib have been used to treat certain forms of cancer, including non-small cell lung cancer.5,6

1.Pollack, V.A., Savage, D.M., Baker, D.A., et al.Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic miceJ. Pharmacol. Exp. Ther.291(2)739-748(1999) 2.Greulich, H., Chen, T.H., Feng, W., et al.Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutantsPLoS Med.2(11)(2005) 3.Yamasaki, F., Zhang, D., Bartholomeusz, C., et al.Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activityMol. Cancer Ther.6(8)2168-2177(2007) 4.Li, Z., Xu, M., Xing, S., et al.Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growthJ. Biol. Chem.282(6)3428-3432(2007) 5.Herbst, R.S., and Bunn, P.A., Jr.Targeting the epidermal growth factor receptor in non-small cell lung cancerClin. Cancer Res.9(16)5813-5824(2003) 6.Gerber, D.E.EGFR inhibition in the treatment of non-small cell lung cancerDrug Dev. Res.69(6)359-372(2008)

实验参考方法

Kinase experiment:

The kinase reaction is performed in 50 μL of 50 mM HEPES (pH 7.3), containing 125 mM NaCl, 24 mM MgCl2, 0.1 mM Na3VO4, 20 μM ATP, 1.6 μg/mL EGF, and 15 ng of EGFR, affinity purified from A431 cell membranes. The compound in DMSO is added to give a final DMSO concentration of 2.5%. Phosphorylation is initiated by addition of ATP and proceeded for 8 mm at room temperature, with constant shaking. The kinase reaction is terminated by aspiration of the reaction mixture and is washed 4 times with wash buffer. Phosphorylated PGT is measured by 25 mim of incubation with 50 μL per well HRP-conjugated PY54 antiphosphotyrosine antibody, diluted to 0.2 μg/mL in blocking buffer (3% BSA and 0.05% Tween 20 in PBS). Antibody is removed by aspiration, and the plate is washed 4 times with wash buffer. The colonmetric signal is developed by addition of TMB Microwell Peroxidase Substrate, 50 μL per well, and stopped by the addition of 0.09 M sulfuric acid, 50μL per well. Phosphotyrosine is estimated by measurement of absorbance at 450 nm. The signal for controls is typically 0.6-1.2 absorbance units, with essentially no back ground in wells without AlP, EGFR, or POT and is proportional to the time of incubation for 10 mm[1].

Cell experiment:

To test the viability of cells treated with B-DIM, Erlotinib, or the combination, BxPC-3 and MIAPaCa cells are plated (3,000-5,000 per well) in a 96-well plate and incubated overnight at 37°C. A range of concentrations for both B-DIM (10-50 µM) and Erlotinib (1-5 µM) is initially tested. Based on the initial results, the concentration of B-DIM (20 µM) and Erlotinib (2 µM) are chosen for all assays. The effects of B-DIM (20 µM), Erlotinib (2 µM), and the combination on BxPC-3 and MIAPaCa cells are determined by the standard MTT assay after 72 h and is repeated three times. The color intensity is measured by a Tecan microplate fluorometer at 595 nm. DMSO-treated cells are considered to be the untreated control and assigned a value of 100%. In addition to the above assay, we have also done clonogenic assay for assessing the effects of treatment[2].

Animal experiment:

Mice[3] Bcrp1/Mdr1a/1b-/- and WT mice are treated p.o. or i.p. with 5 mg/kg Erlotinib. The i.p. administration is chosen assuming good drug absorption and complete bioavailability. Sampling is done from the tip of the lateral tail vein in three series. During the first series, whole blood samples are collected at 15 min and 0.5, 1.5, 5, and 10 h after injection. Based on the results of this initial group, the sampling times of the two subsequent series are adapted to 5 and 15 min and 0.5, 1.5, 4, and 8 h after injection. After collection, the blood samples are immediately centrifuged and plasma is stored at -20°C until high-performance liquid chromatographic analysis took place. Rats[4] Seven-week-old male Crl:CD (SD) rats (244-297 g) are used. The animals are treated with Erlotinib (10 mg/kg and 20 mg/kg) orally by gavage.

References:

[1]. Moyer JD, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997 Nov 1;57(21):4838-48.
[2]. Ali S, et al. Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther, 2008, 7(6), 1708-1719.
[3]. Marchetti S, et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.Mol Cancer Ther. 2008 Aug;7(8):2280-7.
[4]. Adachi K, et al. Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats. J Toxicol Sci. 2010 Aug;35(4):503-14.

化学性质

Cas No. 248594-19-6 SDF
别名 埃罗替尼甲磺酸盐; CP-358774 mesylate; NSC 718781 mesylate; OSI-774 mesylate
Canonical SMILES CS(=O)(O)=O.COCCOC1=CC2=NC=NC(NC3=CC=CC(C#C)=C3)=C2C=C1OCCOC
分子式 C23H27N3O7S 分子量 489.54
溶解度 Soluble in DMSO 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.0427 mL 10.2137 mL 20.4273 mL
5 mM 0.4085 mL 2.0427 mL 4.0855 mL
10 mM 0.2043 mL 1.0214 mL 2.0427 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

产品文档

Quality Control & SDS

View current batch: